4 quarters tracked · Beat rate 75% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $4.40 | $4.47 | +1.7% | Beat |
| Q4 2025 | 2025-12-31 | $5.17 | $5.03 | -2.8% | Miss |
| Q3 2025 | 2025-09-30 | $4.65 | $4.80 | +3.1% | Beat |
| Q2 2025 | 2025-06-30 | $4.37 | $4.52 | +3.4% | Beat |
Earnings Beat Rate
Vertex Pharmaceuticals has beaten analyst EPS estimates in 3 of 4 tracked quarters (75% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →